Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network …
Objective To evaluate sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-
like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying …
like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes at varying …
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors are effective antidiabetic
therapies in patients with type 2 diabetes mellitus and are associated with improved …
therapies in patients with type 2 diabetes mellitus and are associated with improved …
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 …
Background In the SURPASS-4 trial, the dual GIP and GLP-1 receptor agonist tirzepatide
reduced HbA 1c concentrations, bodyweight, and blood pressure more than titrated daily …
reduced HbA 1c concentrations, bodyweight, and blood pressure more than titrated daily …
Effects of SGLT2 inhibitors on kidney and cardiovascular function
SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …
KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease
IH de Boer, ML Caramori, JCN Chan… - Kidney …, 2020 - kidney-international.org
This is an opportune time to publish the first KDIGO 2020 Clinical Practice Guideline for
Diabetes Management in Chronic Kidney Disease (CKD). Worldwide, the estimated number …
Diabetes Management in Chronic Kidney Disease (CKD). Worldwide, the estimated number …
Pharmacotherapy of type 2 diabetes: An update and future directions
A DeMarsilis, N Reddy, C Boutari, A Filippaios… - Metabolism, 2022 - Elsevier
Abstract Type 2 diabetes (T2D) is a widely prevalent disease with substantial economic and
social impact for which multiple conventional and novel pharmacotherapies are currently …
social impact for which multiple conventional and novel pharmacotherapies are currently …
The tubular hypothesis of nephron filtration and diabetic kidney disease
V Vallon, SC Thomson - Nature Reviews Nephrology, 2020 - nature.com
Kidney size and glomerular filtration rate (GFR) often increase with the onset of diabetes,
and elevated GFR is a risk factor for the development of diabetic kidney disease …
and elevated GFR is a risk factor for the development of diabetic kidney disease …
Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin,
and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their …
and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their …
Next generation of fluorine-containing pharmaceuticals, compounds currently in phase II–III clinical trials of major pharmaceutical companies: new structural trends …
Y Zhou, J Wang, Z Gu, S Wang, W Zhu… - Chemical …, 2016 - ACS Publications
Fluoroorganic chemistry has become essential in the evolution of many different but
interconnected research fields. These include the development of new materials with a …
interconnected research fields. These include the development of new materials with a …
Diabetes management in chronic kidney disease: synopsis of the 2020 KDIGO clinical practice guideline
SD Navaneethan, S Zoungas, ML Caramori… - Annals of internal …, 2021 - acpjournals.org
Description: The Kidney Disease: Improving Global Outcomes (KDIGO) organization
developed a clinical practice guideline in 2020 for the management of patients with diabetes …
developed a clinical practice guideline in 2020 for the management of patients with diabetes …